Instil Bio, Inc. TIL
Biotechnology: Biological Products (No Diagnostic Substances) · IPO 2021 · data as of November 13, 2026
Instil Bio, Inc. (TIL) is a healthcare company listed in the US with a market value of about $41M. In the twelve months to June 30, 2026 it had revenue of $9M and net income of -$30M, a net margin of -337.7%.
Its overall Stock Analiz score is 1.2 out of 5 (weak). The strongest part is future growth (3/5); the weakest is value (0/5).
Key numbers: 5-year revenue growth of 130% a year, a 5-year average ROIC of -51%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 31% below the current price.
About Instil Bio
Instil Bio is listed in the US and classified in biotechnology: biological products (no diagnostic substances), IPO year 2021. Revenue went from $138000 in 2020 to $9M in 2025, growth of about 130.4% a year. It was profitable in 0 of the last 6 years in our data. Its share count rose by 3% over three years (dilution for shareholders). It spends 276% of revenue on research and development.
Score: 1.2 / 5
Checks passed
- Revenue growth above 10% last year
- Profit margin improving
- Strong R&D investment or growth above 20%
- 5-year revenue growth above 8% a year
- More cash than debt, or low debt to equity
- Liabilities below 60% of assets
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- 3-year revenue growth above 10% a year
- 3-year free cash flow growth above 10% a year
- 5-year EPS growth above 10% a year
Valuation
Growth and quality
Financials, last 6 years
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|---|
| Revenue | $9M | $9M | $4M | $0 | — | $0 | $138000 |
| Net income | -$30M | -$71M | -$74M | -$156M | -$223M | -$157M | -$38M |
| Free cash flow | — | — | -$56M | -$103M | -$265M | -$180M | -$80M |
| EPS (diluted) | $-4.43 | $-10.70 | $-11.39 | $-24.00 | $-34.46 | $-29.60 | $-47.20 |
| Net margin | -337.7% | -795.9% | -1737.4% | — | — | — | -27346.4% |
| ROIC | — | -68.8% | -33.8% | -69.1% | -60.5% | -22.1% | — |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
Frequently asked questions
Is Instil Bio stock undervalued?
Our DCF model with moderate assumptions puts its intrinsic value about 31% below the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.
Does Instil Bio pay a dividend?
Not currently.
Is Instil Bio a good stock to buy?
We do not give buy or sell advice. Instil Bio scores 1.2 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.